518044-40-1

Basic information

• Product Name: Maleimido-Tri(Ethylene Glycol)-Propionic Acid
• Synonyms: Maleimido-Tri(Ethylene Glycol)-Propionic Acid;3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-hydroxy-2,2-bis(2-hydroxyethyl)pentanoic acid;Mal-PEG3-acid;Maleimide-PEG3-CH2CH2COOH;Mal-PEG3-COOH;Mal-PEG3-CH2CH2COOH
• CAS NO: 518044-40-1
• Molecular Formula: C₁₃H₁₉NO₇
• Molecular Weight: 301.29
• Mol File: 518044-40-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 491.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.293±0.06 g/cm3(Predicted)
• PKA: 4.28±0.10(Predicted)
• CAS DataBase Reference: Maleimido-Tri(Ethylene Glycol)-Propionic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: Maleimido-Tri(Ethylene Glycol)-Propionic Acid(518044-40-1)
• EPA Substance Registry System: Maleimido-Tri(Ethylene Glycol)-Propionic Acid(518044-40-1)

Safety Data

• Hazardous Substances Data: 518044-40-1(Hazardous Substances Data)

Usage

Description

Mal-PEG3-acid is a PEG linker containing a maleimide group with a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The maleimide group will react with a thiol group to form a covalent bond, enabling the connection of biomolecule with a thiol. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.

Upstream product

• 108-31-6 maleic anhydride 
• 784105-33-5 3-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}propanoic acid 
• 518044-35-4 tert-butyl 3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoate 
• 252881-74-6 tert-butyl 3-(2-(2-(2-aminoethoxyl)ethoxy)ethoxy)propanoate 
• 55750-48-6 N-methoxycarbonylmaleimide 
• 1404072-05-4 3-{2-[2-(2-aminoethoxyl)ethoxy]ethoxy}propanoic acid trifluoroacetate 

Downstream Products

• 76-05-1 trifluoroacetic acid 
• 1807534-78-6 perfluorophenyl 3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethoxy)ethoxy)propanoate 
• 1537892-36-6 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethoxy)ethoxy)propanoate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS

The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.

NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF

The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

Novel Binder-Drug Conjugates (ADCs) and Use of Same

The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.